Estrogen receptor-IN-2
Estrogen receptor-IN-2 is a potent estrogen receptor inhibitor formed by the conjugation of Tam (HY-13757)-NHC and gold (I). Estrogen receptor-IN-2 significantly downregulates estrogen receptor (ER) levels, inhibits ER-mediated downstream signaling pathways, and induces immunogenic cell death (ICD) mediated by damage-associated molecular patterns (DAMPs). Estrogen receptor-IN-2 can overcome drug resistance in MCF-7Y537S mutant cells via the RAMP3/CALCR signaling pathway. It is suitable for research on endocrine-resistant breast cancer.
For research use only. We do not sell to patients.
- Formula: C55H63AuBr2N5O5
- Molecular Weight:1230.89
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
JNK |
p38 |
ERαY537S |
ERαWT |
ERRα |
Estrogen receptor |
GRP78 |
Cellular Effect
In Vitro
Estrogen receptor-IN-2 (compound 7b) (72 h) exhibits significant antiproliferative activity in MCF-7 cells (IC50 = 0.38 μM) and Ishikawa cells (IC50 = 0.75 μM)[1].
Estrogen receptor-IN-2 (120 h) demonstrates antiproliferative activity that overcomes endocrine resistance in MCF-7Y537S cells (IC50 = 0.16 μM) and MCF-7D538G cells (IC50 = 0.52 μM)[1].
Estrogen receptor-IN-2 (0.5-4 μM; 24 h) downregulates ERα protein expression in MCF-7 cells[1].
Estrogen receptor-IN-2 (24 h) antagonizes ERE transcriptional activity in MCF-7 cells[1].
Estrogen receptor-IN-2 (0.5-2 μM; 24 h) inhibits the expression of ER downstream genes (PR and TFF-1) in MCF-7 cells. Estrogen receptor-IN-2 inhibits thioredoxin reductase (TrxR) activity in a dose-dependent manner in MCF-7 cells. Estrogen receptor-IN-2 activates the ASK1/JNK/p38 signaling pathway in MCF-7 cells[1].
Estrogen receptor-IN-2 (12 h) induces specific mitochondrial and cytoplasmic distribution in MCF-7 cells[1].
Estrogen receptor-IN-2 (0.5-4 μM; 12 h) increases intracellular reactive oxygen species (ROS) levels in MCF-7 cells. Estrogen receptor-IN-2 induces a decrease in mitochondrial membrane potential and mitochondrial dysfunction in MCF-7 cells. Estrogen receptor-IN-2 triggers the release of intracellular calcium ions in MCF-7 cells[1].
Estrogen receptor-IN-2 (0.5-4 μM; 24 h) induces endoplasmic reticulum stress (ERS) in MCF-7 cells. Estrogen receptor-IN-2 causes cell cycle arrest at the G0/G1 phase and induces apoptosis in MCF-7 cells[1].
Estrogen receptor-IN-2 (4 μM; 3-24 h) induces the release of immunogenic cell death (ICD) markers in MCF-7 cells[1].
Estrogen receptor-IN-2 (2-10 μM; 24 h) downregulates the drug resistance-associated RAMP3/CALCR signaling pathway and gene expression in MCF-7Y537S cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF-7 cells
-
Concentration:0.5 μM, 1 μM, 2 μM, 4 μM
-
Incubation Time:24 h
-
Result:Downregulated the ERα protein level in a dose-dependent manner.
Increased the ratios of p-ASK1/ASK1, p-JNK/JNK, and p-p38/p38, activating the downstream pathway.
Upregulated the expression of endoplasmic reticulum stress-related proteins (Calnexin, GRP78, ATF-4, and CHOP), as well as CRT and HMGB1.
-
Cell Line:MCF-7 cells, MCF-7Y537S cells
-
Concentration:0.5 μM, 1 μM, 2 μM
-
Incubation Time:24 h
-
Result:Inhibited the expression of PR and TFF-1 genes.
Significantly reduced the expression of resistance-associated RAMP3 and CALCR genes.
-
Cell Line:MCF-7 cells
-
Concentration:0.5 μM, 1 μM, 2 μM, 4 μM
-
Incubation Time:12 h, 24 h
-
Result:Decreased ER protein levels.
Increased ROS levels.
Increased the expression of endoplasmic reticulum stress markers such as Calnexin and GRP78.
Promoted HMGB1 release and CRT cell membrane exposure.
-
Cell Line:MCF-7 cells
-
Concentration:0.5 μM, 1 μM, 2 μM, 4 μM
-
Incubation Time:24 h
-
Result:Resulted in cell cycle arrest at the G0/G1 phase.
-
Cell Line:MCF-7 cells
-
Concentration:0.5 μM, 1 μM, 2 μM, 4 μM
-
Incubation Time:24 h
-
Result:Induced apoptosis in a dose-dependent manner.
In Vivo
Estrogen receptor-IN-2 (10 mg/kg; i.p.; every other day; for 24 days) exhibits the activity to overcome drug resistance, significantly inhibit tumor growth, and downregulate the expression of ER, PR, and Ki67 in tumor tissues in female BALB/c nude mice (42-48 days old, subcutaneous mutant MCF-7Y537S xenograft model)[1].
Estrogen receptor-IN-2 (10 mg/kg; i.p.; once a day; for 2 days) demonstrates a good safety profile in immature female SD rats (weighing approximately 100 g)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice (42-48-day-old, female) were inoculated subcutaneously with 1 × 106 wild-type MCF-7 cells[1].
-
Dosage:10 mg/kg
-
Administration:i.p.; every other day; for 24 days
-
Result:Significantly inhibited tumor growth and decreased tumor volume and weight.
Caused no obvious mouse body weight loss or morphological damage to organs (heart, liver, spleen, lung, kidney)
Significantly downregulated the expression levels of ER, PR, and Ki67 in tumor tissues.
-
Animal Model:BALB/c nude mice (42-48-day-old, female) were inoculated subcutaneously with 1 × 106 mutant MCF-7Y537S cells[1].
-
Dosage:10 mg/kg
-
Administration:i.p.; every other day; for 24 days
-
Result:Overcame endocrine resistance and significantly inhibited mutant tumor growth and significantly decreased tumor volume and weight.
Caused no obvious mouse body weight loss or organ damage during treatment.
Significantly downregulated the expression levels of ER, PR, and Ki67 in tumor tissues.
-
Animal Model:SD rats (immature female, approximately 100 g) [1].
-
Dosage:10 mg/kg
-
Administration:i.p.; once daily; for 2 days
-
Result:Reduced the uterine wet weight.
Exhibited no significant estrogenic agonistic effects, indicating a good safety profile.
Chemical Information
-
Molecular Weight 1230.89
-
Formula C55H63AuBr2N5O5
-
SMILES
CN(CCOC1=CC=C(/C(C2=CC=CC=C2)=C(CC)\C3=CC=CC=C3)C=C1)C(OCCC[N+]4=C([Au]C5=[N+](CC)C(C6=CC=C(OC)C=C6)=C(C7=CC=C(OC)C=C7)N5CC)N(CC)C=C4)=O.[Br-].[Br-]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)